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Rituximab-induced hypogammaglobulinemia and intravenous immunoglobulin 





Rituximab (RTX) is effective in inducing and maintaining remission in granulomatous 
with polyangiitis (GPA) patients. RTX decreases serum levels of immunoglobulin 
leading to hypogammaglobulinemia and infections in some patients. This study aims 




The study included 35 GPA patients from our vasculitis registry who received long-
term pre-emptive RTX maintenance between April 2004 and June 2011. 54 % were 
men; they were 50 (14-81) years old and had received 16 (0-250) g 
cyclophosphamide. They received a RTX cumulative dose of 9 (2-14) g and were 
followed during 77 months. Hypogammaglobulinemia was defined as total Ig < 6 g/L. 
 
Results: 
Nineteen patients (54%) developed hypogammaglobulinemia 33 (4-71) months after 
RTX initiation and RTX was re-administered in 16. Seven patients (20 %) received 
IVIG 31 (0-43) months after hypogammaglobulinemia diagnosis.  
Two patients discontinued IVIG after 3 and 4 months; however 5 patients were still 
on IVIG at last visit, receiving 360 (150-390) g yearly in the past 3 years. Total Ig 
levels increased from 4.7 prior IVIG to 7.4 g/L.  
Eight patients (23 %) relapsed after 3 years of RTX maintenance: 5 had 
hypogammaglobulinemia and 4 required IVIG. All 3 relapsing patients with subglottic 




The risk of hypogammaglobulinemia and the need for IVIG increase during long-term 
RTX maintenance in GPA.  If required to treat hypogammaglobulinemia, IVIG use is 
usually prolonged. RTX-induced hypogammaglobulinemia and IVIG do not protect 
against relapse.  
 
 
 
 
